On October 25, 2011, the Indianapolis Lawyers Chapter of the Federalist Society hosted a debate between Indiana Solicitor General Thomas Fisher and Prof. Gerard Magliocca of Indiana University School of Law - Indianapolis on the constitutionality of the Health Care Reform Act. Introduction by Mr. Brian J. Paul of Ice Miller LLP and President of the Indianapolis Lawyers Chapter.
In this issue, we offer an overview of the ABA’s policy on gun control, offered in light of the recent decision in the Heller case. We also discuss an ethical issue concerning attorneys fees by the ABA Standing Committee on Ethics and Professional Responsibility considered last Fall. We also profile several of the award winners at the ABA’s Annual Meeting. And, as in the past, we digest and summarize actions before the House of Delegates. [More]
In May 2006, a panel of the U.S. Court of Appeals for the District of Columbia Circuit ruled that terminally ill patients posses a fundamental right to access experimental drugs (drugs that have passed phase I but not phases II or III of FDA testing) that have not been fully approved by the Food and Drug Administration. However, in August of this year, a divided appeals court sitting en banc reversed that decision in Abigail Alliance v. von Eschenbach. On September 28, 2007, the Washington Legal Foundation submitted a cert petition to the Court on behalf of Abigail Alliance for Better Access to Developmental Drugs. The Supreme Court is likely to decide by January whether to hear the case. A panel of experts including Vice President for Legal Affairs at Cato, Roger Pilon, President of the Ethics & Public Policy Center, Ed Whelan, Case Western University of Law professor Jonathan Adler, and General Counsel for the Committee for Justice, Curt Levey, consider whether the terminally ill have a fundamental constitutional right to access potentially life saving drugs.